CIK 1855655
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 80.34% | 31 |
| Unclassified | 18.83% | 3 |
| Life Sciences Tools & Services | 0.83% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ARCELLX INC | Unclassified | 13.55% | |
| 2 | RVMD | Revolution Medicines, Inc. | Health Care | 13.23% |
| 3 | NUVL | Nuvalent, Inc. | Health Care | 11.15% |
| 4 | PCVX | Vaxcyte, Inc. | Health Care | 5.69% |
| 5 | EWTX | Edgewise Therapeutics, Inc. | Health Care | 4.74% |
| 6 | GMAB | GENMAB A/S | Health Care | 4.37% |
| 7 | INSM | INSMED Inc | Health Care | 4.19% |
| 8 | TARS | Tarsus Pharmaceuticals, Inc. | Health Care | 3.67% |
| 9 | BLTE | BELITE BIO, INC | Health Care | 3.63% |
| 10 | ERAS | Erasca, Inc. | Health Care | 3.44% |
32/35 names classified · sector 81.2% of weight · industry 81.2% · mkt cap 71.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 81.2% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/33 names) · unclassified 100.0%: , RVMD, NUVL, PCVX, EWTX, GMAB, INSM, TARS, BLTE, ERAS +23 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ARCELLX INC | 5,774,016 | $663M | 13.5% | HOLD |
| 2 | RVMDREVOLUTION MEDICINES INC | 6,655,703 | $647M | 13.2% | HOLD |
| 3 | NUVLNUVALENT INC | 5,324,433 | $545M | 11.1% | HOLD |
| 4 | PCVXVAXCYTE INC | 4,793,020 | $279M | 5.7% | ADD 18% |
| 5 | EWTXEDGEWISE THERAPEUTICS INC | 7,365,038 | $232M | 4.7% | ADD 13% |
| 6 | GMABGENMAB A/S | 7,967,836 | $214M | 4.4% | ADD 13% |
| 7 | INSMINSMED INC | 1,254,488 | $205M | 4.2% | NEW |
| 8 | TARSTARSUS PHARMACEUTICALS INC | 2,562,154 | $180M | 3.7% | HOLD |
| 9 | BLTEBELITE BIO INC | 1,114,784 | $178M | 3.6% | NEW |
| 10 | ERASERASCA INC | 10,392,702 | $168M | 3.4% | TRIM −27% |
| 11 | CENTESSA PHARMACEUTICALS PLC | 3,574,048 | $142M | 2.9% | NEW |
| 12 | OLMAOLEMA PHARMACEUTICALS INC | 8,020,576 | $120M | 2.4% | ADD 6% |
| 13 | TERNS PHARMACEUTICALS INC | 2,216,499 | $117M | 2.4% | ADD 174% |
| 14 | ORKAORUKA THERAPEUTICS INC | 2,320,316 | $114M | 2.3% | ADD 36% |
| 15 | APGEAPOGEE THERAPEUTICS INC | 1,348,243 | $113M | 2.3% | ADD 20% |
| 16 | SYRESPYRE THERAPEUTICS INC | 1,957,266 | $99M | 2.0% | ADD 33% |
| 17 | CYTKCYTOKINETICS INC | 1,480,857 | $98M | 2.0% | NEW |
| 18 | ABVXABIVAX SA | 772,473 | $86M | 1.8% | TRIM −46% |
| 19 | TNGXTANGO THERAPEUTICS INC | 4,009,679 | $84M | 1.7% | NEW |
| 20 | MAZEMAZE THERAPEUTICS INC | 2,744,399 | $82M | 1.7% | NEW |
| 21 | TYRATYRA BIOSCIENCES INC | 2,054,991 | $79M | 1.6% | NEW |
| 22 | VRDNVIRIDIAN THERAPEUTICS INC | 3,148,893 | $62M | 1.3% | ADD 118% |
| 23 | SRRKSCHOLAR ROCK HLDG CORP | 1,226,080 | $60M | 1.2% | TRIM −60% |
| 24 | MIRMMIRUM PHARMACEUTICALS INC | 625,000 | $58M | 1.2% | NEW |
| 25 | EYPTEYEPOINT INC | 3,142,437 | $41M | 0.8% | TRIM −15% |
| 26 | LXEOLEXEO THERAPEUTICS INC | 6,184,134 | $35M | 0.7% | ADD 30% |
| 27 | MANEVeradermics Inc | 525,000 | $33M | 0.7% | NEW |
| 28 | VORVOR BIOPHARMA INC | 1,750,000 | $31M | 0.6% | HOLD |
| 29 | URGNUROGEN PHARMA LTD | 1,703,949 | $31M | 0.6% | TRIM −62% |
| 30 | GPCRSTRUCTURE THERAPEUTICS INC | 545,287 | $26M | 0.5% | NEW |
| 31 | IVAINVENTIVA SA | 4,000,000 | $22M | 0.5% | HOLD |
| 32 | ORICORIC PHARMACEUTICALS INC | 1,701,217 | $22M | 0.4% | TRIM −29% |
| 33 | ASMBASSEMBLY BIOSCIENCES INC | 665,251 | $18M | 0.4% | HOLD |
| 34 | BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | 868,213 | $8M | 0.2% | TRIM −62% |
| 35 | KLRSKALARIS THERAPEUTICS INC | 700,000 | $4M | 0.1% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ARCELLX INC | 4.4M | 4.5M | 4.6M | 4.6M | 5.7M | 5.8M | $663M |
| RVMDREVOLUTION MEDICINES INC | 6.6M | 6.2M | 6.1M | 6.2M | 6.6M | 6.7M | $647M |
| NUVLNUVALENT INC | 5.4M | 5.3M | 5.3M | 5.3M | 5.3M | 5.3M | $545M |
| PCVXVAXCYTE INC | 1.4M | 1.7M | 3.4M | 3.8M | 4.1M | 4.8M | $279M |
| EWTXEDGEWISE THERAPEUTICS INC | 4.5M | 4.4M | 6.1M | 6.2M | 6.5M | 7.4M | $232M |
| GMABGENMAB A/S | — | — | — | 3.8M | 7.0M | 8.0M | $214M |
| INSMINSMED INC | — | 451K | — | — | — | 1.3M | $205M |
| TARSTARSUS PHARMACEUTICALS INC | 2.5M | 2.6M | 3.0M | 2.7M | 2.6M | 2.6M | $180M |
| BLTEBELITE BIO INC | — | — | — | — | — | 1.1M | $178M |
| ERASERASCA INC | 10.8M | 10.8M | 11.9M | 13.6M | 14.2M | 10.4M | $168M |
| CENTESSA PHARMACEUTICALS PLC | — | — | — | — | — | 3.6M | $142M |
| OLMAOLEMA PHARMACEUTICALS INC | 7.3M | 6.7M | 6.8M | 6.8M | 7.5M | 8.0M | $120M |
| TERNS PHARMACEUTICALS INC | — | — | — | — | 810K | 2.2M | $117M |
| ORKAORUKA THERAPEUTICS INC | 820K | — | — | — | 1.7M | 2.3M | $114M |
| APGEAPOGEE THERAPEUTICS INC | 1.3M | 962K | 959K | 1.5M | 1.1M | 1.3M | $113M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
